Table 1.
Clinical characteristics of the patients with breast carcinoma.
Figure 1.
Immunohistochemical detection of tumor-associated macrophages (marker CD68) in breast cancer tissues.
(A) High-infiltration specimen (x 100) (B) High-infiltration specimen (x 400) (C) Low-infiltration specimen (x 100) (D) Low-infiltration specimen (x 400).
Table 2.
Correlation of TAM expression with prognosis.
Table 3.
Correlation between CD68 expression and various clinicopathological features.
Figure 2.
Kaplan–Meier analysis for DFS and OS based on CD68 expression in breast cancer patients.
(A) Kaplan–Meier analysis for DFS based on CD68 expression in patients with breast cancer (log-rank test, P = 0.012) (B) Kaplan–Meier analysis for OS based on CD68 expression in patients with breast cancer (log-rank test, P<0.001). Green: TAM-low group; Blue: TAM-high group.
Figure 3.
Overall survival and disease-free interval according to clinical stage and lymph node status.
(A) DFS in stage I-II patients, P = 0.027 (B) OS in stage I-II patients, P = 0.025 (C) DFS in stage III patients, P = 0.134 (D) OS in stage III patients, P<0.001 (E) DFS in node-negative patients, P = 0.033 (F) OS in node-negative patients, P = 0.013. Green: TAM-low group; Blue: TAM-high group.
Table 4.
Prognostic factors in the Cox proportional hazards model.